Roche licenses RNAi product development to Tekmira
This article was originally published in Scrip
Executive Summary
Tekmira Pharmaceuticals has agreed to advance Roche's first two RNAi products into human clinical studies. The small interfering RNA candidates will be based on the Canadian firm's stable nucleic acid-lipid particle technology.